Literature DB >> 8754227

Assessing substance use disorder in persons with severe mental illness.

R E Drake1, S D Rosenberg, K T Mueser.   

Abstract

Assessment of dually diagnosed patients consists of three steps: detection, diagnosis, and specialized assessment for treatment planning. Each of these is informed by recent research.

Entities:  

Mesh：

Year:  1996        PMID： 8754227     DOI： 10.1002/yd.23319960203

Source DB:  PubMed          Journal:  New Dir Ment Health Serv        ISSN： 0193-9416


  26 in total

1.  Further validation of the Psycho-Social Well-Being Scale (PSWS) with community clients.

Authors:  Thomas O'Hare; Margaret V Sherrer; Hilary Smith Connery; Jay Thornton; Annamaria LaButti; Kelly Emrick
Journal:  Community Ment Health J       Date:  2003-04

Review 2.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 3.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

4.  Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders.

Authors:  R E Clark; G B Teague; S K Ricketts; P W Bush; H Xie; T G McGuire; R E Drake; G J McHugo; A M Keller; M Zubkoff
Journal:  Health Serv Res       Date:  1998-12       Impact factor: 3.402

5.  First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial.

Authors:  Vinod H Srihari; Cenk Tek; Suat Kucukgoncu; Vivek H Phutane; Nicholas J K Breitborde; Jessica Pollard; Banu Ozkan; John Saksa; Barbara C Walsh; Scott W Woods
Journal:  Psychiatr Serv       Date:  2015-02-02       Impact factor: 3.084

6.  Abstinence and Use of Community-Based Cessation Treatment After a Motivational Intervention Among smokers with Severe Mental Illness.

Authors:  Joelle C Ferron; Timothy Devitt; Gregory J McHugo; Jessica A Jonikas; Judith A Cook; Mary F Brunette
Journal:  Community Ment Health J       Date:  2016-03-01

7.  Predictors of Depressive Symptomatology in Family Caregivers of Women With Substance Use Disorders or Co-Occurring Substance Use and Mental Disorders.

Authors:  David E Biegel; Shiri Katz-Saltzman; David Meeks; Suzanne Brown; Elizabeth M Tracy
Journal:  J Fam Soc Work       Date:  2010

8.  Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies.

Authors:  Rune A Kroken; Eirik Kjelby; Tore Wentzel-Larsen; Liv S Mellesdal; Hugo A Jørgensen; Erik Johnsen
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

9.  Cardiovascular mortality in schizophrenia: defining a critical period for prevention.

Authors:  Vinod H Srihari; Vivek H Phutane; Banu Ozkan; Lydia Chwastiak; Joseph C Ratliff; Scott W Woods; Cenk Tek
Journal:  Schizophr Res       Date:  2013-02-17       Impact factor: 4.939

10.  Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.

Authors:  Erik Johnsen; Rune A Kroken; Tore Wentzel-Larsen; Hugo A Jørgensen
Journal:  BMC Psychiatry       Date:  2010-03-24       Impact factor: 3.630
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.